title: Vardenafil in the treatment of erectile dysfunction in outpatients with chronic schizophrenia: a flexible-dose, open-label study.
abstract: OBJECTIVE
  The aim of this study was to evaluate the safety and efficacy of vardenafil in outpatients with chronic schizophrenia and erectile dysfunction and to investigate any effect on quality of life in this population.
  
  
  METHODS
  In this 12-week, open-label, flexible-dose study, 25 outpatients with chronic schizophrenia (DSM-IV criteria) and erectile dysfunction received vardenafil 10 mg as needed (at a maximum of 1 dose per day) with the option to maintain current dose or to titrate to 5 mg or 20 mg at 4 and 8 weeks. Assessment was performed with the International Index of Erectile Function (IIEF) at base line and at weeks 4, 8, and 12. The Quality of Life Scale (QLS) was administered at baseline and at week 12. The study was carried out at the Psychiatric Hospital of Athens, Greece, between October 2005 and November 2006.
  
  
  RESULTS
  Vardenafil produced a statistically significant improvement in all IIEF domains [erectile function (p < .001), orgasmic function (p < .05), sexual desire (p < .05), intercourse satisfaction (p < .01), and overall satisfaction (p < .001)] and QLS (p < .003). Results were similar for the intention-to-treat (N = 25) and completer (N = 21, 84%) groups. Adverse events were infrequent and decreased in incidence over the course of the study.
  
  
  CONCLUSIONS
  Vardenafil was generally well tolerated and highly effective in outpatients with chronic schizophrenia and erectile dysfunction. The response to vardenafil was not influenced by certain patient characteristics, such as erectile dysfunction severity or serum prolactin levels. Improvement in sexual function was correlated with improvement in the quality of life.
authors.affiliation: Psychiatric Hospital of Athens, Athens University Medical School, Athens, Greece. ectorcenter@yahoo.gr
authors.forename: Charalampos I
authors.initials: CI
authors.lastname: Mitsonis
authors.forename: Panagiotis A
authors.initials: PA
authors.lastname: Mitropoulos
authors.forename: Nikolaos P
authors.initials: NP
authors.lastname: Dimopoulos
authors.forename: Evangelia G
authors.initials: EG
authors.lastname: Kararizou
authors.forename: Vasiliki V
authors.initials: VV
authors.lastname: Psarra
authors.forename: Fivos E
authors.initials: FE
authors.lastname: Tsakiris
authors.forename: Maria-Nefeli E
authors.initials: MN
authors.lastname: Katsanou
mesh_terms: D000328:Adult; D000368:Aged; D000704:Analysis of Variance; D002908:Chronic Disease; D004334:Drug Administration Schedule; D007172:Erectile Dysfunction / Q000097:blood / Q000150:complications* / Q000188:drug therapy*; D006115:Greece; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009948:Orgasm; D010045:Outpatients; D017060:Patient Satisfaction; D010410:Penile Erection / Q000187:drug effects; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use; D010879:Piperazines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011388:Prolactin / Q000097:blood; D011446:Prospective Studies; D011788:Quality of Life; D012107:Research Design; D012559:Schizophrenia / Q000150:complications*; D013450:Sulfones / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D013997:Time Factors; D016896:Treatment Outcome; D014227:Triazines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000069058:Vardenafil Dihydrochloride
chemical_list: D007093:Imidazoles; D010726:Phosphodiesterase Inhibitors; D010879:Piperazines; D013450:Sulfones; D014227:Triazines; D000069058:Vardenafil Dihydrochloride; D011388:Prolactin